Project Grant DP2AR082471
- This $256,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program will support the development of additive manufacturing techniques for soft tissue repair. Asante Bio LLC will receive funding to design and engineer a novel 3D microfiber printer capable of assembling synthetic biopolymer filaments into fibrous, flexible implants that promote soft tissue healing. Through this six-month award ending November 2022, Asante Bio will optimize...
- Federal Project Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded The Pennsylvania State University a $685,594 Project Grant on June 16, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121) to develop innovative surgical and bioprinting technologies for reconstructive surgery. The award funds research into "Leveraging Microsurgery and Bioprinting for Rapidly Oriented Vascularized Tissue Engineering," with a project...
- This federal Project Grant award of $460,500 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) is aimed at developing novel bioprinting methodologies for the production of human stem cell-based organoids. The key objectives are to: 1) Create a customized bioink formulation using proteins, polysaccharides, and functionalized nanoparticles to foster the...
- This Project Grant awarded by the National Science Foundation (CFDA 47.041 - Engineering) to Cleveland State University (CSU) provides $500,000 in funding from January 1, 2025 to December 31, 2027 to develop bioprinted tissue scaffolds with Schwann cell density gradients and electrical conductivity for peripheral nerve regeneration. The goal is to understand how Schwann cell density gradients and electrical properties within the scaffolds can enhance the regeneration of injured peripheral...
- The National Science Foundation (NSF) awarded a Project Grant through its Directorate for Technology, Innovation, and Partnerships (CFDA 47.084) to Georgia Tech Research Corporation in the amount of $249,689 for the project "3D Printed Tissue Implants for Facial Surgery." The project aims to develop a platform for 3D printing tissue implants for facial surgery, enabling the design and rapid manufacturing of implants for tissue reconstruction. The work will involve evaluating the impact...
- Federal Project Grant Award Summary The National Science Foundation's Division of Civil, Mechanical, and Manufacturing Innovation awarded $149,826 to the University of Nebraska Medical Center (effective August 1, 2025 through July 31, 2027) under the Engineering program (CFDA 47.041) to develop an innovative embedded section-by-section bioprinting (ESB) process for fabricating large-scale human tissue constructs. The primary deliverables include: (1) identification of cell damage mechanisms...
- This $635,000 Project Grant awarded by the National Science Foundation (NSF) Division of Civil, Mechanical, and Manufacturing Innovation supports research to understand how mechanical boundary conditions influence tissue assembly and repair in 3D fibrous microtissues. The research aims to advance knowledge about the mechanisms by which mechanical forces regulate new tissue formation and organization, particularly as it relates to wound healing. The project will integrate in vitro experiments and...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 Arthritis, Musculoskeletal and Skin Diseases Research) provides $434,793 to the University of Arkansas to conduct research aimed at developing regenerative and rehabilitation strategies to reduce inflammation and improve muscle recovery following volumetric muscle loss (VML) injuries. The key objectives are to: 1) Determine the efficacy of endurance exercise in attenuating...
- This $305,548 National Science Foundation Engineering grant will support the acquisition of a multi-modal, high-resolution 4D bioprinting platform at North Carolina State University. The platform features laser induced forward transfer, micro-valve drop-on-demand, and micro-extrusion printing capabilities for fundamental research and workforce training in additive manufacturing, tissue engineering, plant and animal cell biology, functional materials engineering, and bioelectronics. With...
- The University of Washington received a $271,664 Project Grant from the National Institute of Biomedical Imaging and Bioengineering under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), effective May 10, 2025, with a completion date of April 30, 2028. This Trailblazer Award supports the development and validation of magnetic microgels as a novel drug delivery platform for musculoskeletal tissue regeneration. The research aims to...
A NOVEL SEMI-AUTONOMOUS SURGEON-IN-THE-LOOP IN SITU ROBOTIC BIOPRINTING SYSTEM FOR FUNCTIONAL AND COSMETIC RESTORATION OF VOLUMETRIC MUSCLE LOSS INJURIES - SUMMARY/ABSTRACT: OUR LONG-GOAL IS TO DEVELOP AN UNPRECEDENTED SEMI-AUTONOMOUS SURGEON-IN-THE-LOOP SURGICAL ROBOTIC SYSTEM AND COMPLEMENTARY COMPUTER-ASSISTED ALGORITHMS TO ENABLE AN INTUITIVE IN SITU ROBOTIC BIOPRINTING OF HUMAN TISSUES AND ORGANS. MORE SPECIFICALLY, USING THIS EXTRUSION-BASED BIOPRINTING SYSTEM, A SURGEON CAN (I) FIRST UTILIZE A HIGH-RESOLUTION THREE-DIMENSIONAL (3D) POINT CLOUD CAMERA TO PLAN AN ARBITRARY SPATIAL PRINTING GEOMETRY ON THE TARGET ANATOMICAL SURFACE, (II) CO-OPERATE WITH A ROBOTIC SYSTEM TO MANIPULATE A CUSTOM- DESIGNED BIOPRINTING INSTRUMENT TO PRECISELY FOLLOW THE PLANNED PRINTING GEOMETRY, AND (III) PERFORM AN INTUITIVE AND PRECISE DEPOSITION OF ENGINEERED BIOINKS TO MAKE TISSUE CONSTRUCTS ON THE TARGET ANATOMICAL SURFACE, WHILE (IV) DIRECTLY CONTROL AND MONITOR THE PRINTING PROCESS TO ENSURE THE SAFETY AND SUCCESS OF THE PROCEDURE. THE FOCUS OF THIS PROPOSAL IS SIMULTANEOUS FUNCTIONAL AND COSMETIC RESTORATION OF LARGE VOLUMETRIC MUSCLE LOSS (VML) INJURIES BY UTILIZING A NOVEL ENGINEERED BIOINK- DEVELOPED BY OUR COLLABORATORS AT THE TERASAKI INSTITUTE OF BIOMEDICAL INNOVATION, A COMPLEMENTARY ROBOTIC BIOPRINTING SYSTEM, AND INTUITIVE COMPUTER- ASSISTED ALGORITHMS. SEVERE MUSCULOSKELETAL INJURIES CAN LEAD TO VML, WHERE EXTENSIVE MUSCULOSKELETAL DAMAGE AND TISSUE LOSS RESULT IN PERMANENT LOSS OF FUNCTION. IN SMALL-SCALE INJURIES OR STRAINS, MUSCLE IS CAPABLE OF ENDOGENOUS REGENERATION AND COMPLETE FUNCTIONAL RESTORATION. HOWEVER, THIS ABILITY IS ABATED IN VML, WHERE THE NATIVE BIOPHYSICAL AND BIOCHEMICAL SIGNALING CUES ARE NO LONGER PRESENT TO FACILITATE TISSUE REGENERATION. CURRENT STATE- OF-THE-ART IN VITRO TISSUE ENGINEERING VML TREATMENT PROCEDURES SUFFER FROM VARIOUS ISSUES INCLUDING (I) PROLONGED CULTURING PERIOD IN BIOREACTORS DEMANDING FUNCTIONALITY ENHANCEMENT PRIOR TO IMPLANTATION IN THE BODY; (II) ADHESION FAILURE OF IN VITRO 3D PRINTED HYDROGEL SCAFFOLDS TO THE REMNANT MUSCLE, WHETHER INJECTED, SUTURED, OR PLACED INTO THE WOUND; AND (III) INABILITY TO BE PRINTED PRECISELY IN IRREGULAR CURVED 3D SURFACES OF LARGE VML INJURIES. IT IS OUR CENTRAL HYPOTHESIS THAT THE PROPOSED SEMI-AUTONOMOUS ROBOTIC BIOPRINTING SYSTEM CAN COLLECTIVELY ADDRESS THE MENTIONED LIMITATIONS OF THE CURRENT STATE-OF-THE-ART SOLUTIONS BY (I) REDUCING COMPLEXITY, SURGICAL TIME, AND COMPLICATIONS ASSOCIATED WITH CURRENT VML TREATMENTS, (II) IMMEDIATELY DELIVERING AND IN SITU PRINTING OF APPROPRIATE BIOINKS TO THE TARGET ANATOMY AND UTILIZING THE HUMAN BODY AS A NATURAL BIOREACTOR TO INDUCE TISSUE MATURATION AND FUNCTION, AND (III) PROVIDING REAL-TIME FEEDBACK ON THE 3D BIOPRINTED CONSTRUCTS AS WELL AS THE SURGEON'S AND PATIENT'S MOTIONS TO ENSURE PRECISION OF THE BIOPRINTING PROCEDURE FOR SIMULTANEOUS FUNCTIONAL AND COSMETIC RESTORATION OF THE INJURED MUSCLE. THE PROPOSED PROJECT IS MULTIDISCIPLINARY AND BRIDGES THE CURRENT GAP BETWEEN THE ROBOTIC SURGERY, TISSUE ENGINEERING, AND BIOPRINTING FIELDS. THE CONTRIBUTION IS SIGNIFICANT, HIGH IMPACT, AND INNOVATIVE AND CAN REVOLUTIONIZE THE CURRENT CLINICAL PARADIGM.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $925.7k | 8/11/25 | ||
| Not listed | $1.4m | 9/2/22 | ||
| Not listed | $1.4m | 9/2/22 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
UTAUSSUB00000862S | Terasaki Institute For Biomedical Innovation | Project Grant DP2AR082471 | $440.1k | 4/29/26 | |
UTAUSSUB00000862S | Terasaki Institute For Biomedical Innovation | Project Grant DP2AR082471 | $75.0k | 3/27/25 | |
UTAUSSUB00000862S | Terasaki Institute For Biomedical Innovation | Project Grant DP2AR082471 | $200.0k | 3/29/24 |